Additional Testing Many tests look for genes, proteins, and other substances (called biomarkers) that provide helpful information about a prostate cancer diagnosis. Jump To Jump To Additional Test Types Biomarkers & Family History The most common screening tool for prostate cancer is the prostate-specific antigen (PSA) blood test. This test is usually the first step in any prostate cancer diagnosis. However, the PSA blood test by itself can't tell you if cancer is present.Recent research has yielded additional tests which look for genes, proteins, and other substances (called biomarkers or tumor markers) that can provide information about cancer. These tests, in addition to the PSA, DRE (Digital Rectal Exam), and biopsy, can give doctors and patients more information on how to determine the probability of both finding cancer during a biopsy and determining how aggressive that cancer is likely to be. Additional screening and diagnostic tests While none of these tests are conclusive on their own, when performed in addition to a PSA test, DRE, and a biopsy, they can provide you with more information about your specific cancer and can help in making decisions about your care. 4KScore A blood test providing patient-specific probability of finding an aggressive form of prostate cancer during a biopsy. Doctors and patients can then make an informed decision on whether to have a biopsy. The test measures total PSA, free PSA, intact PSA, and for certain enzymes called kallikrein. An algorithm used with the patient’s age and physical exam gives a probability percentage of having aggressive disease. ConfirmMDX For patients with an initial negative biopsy, the ConfirmMDx test can make a significant prediction of patient outcome compared to other factors alone such as age, PSA and DRE results, race, and family history. It can help avoid repeat biopsies. EpiSwitch® PSE A simple blood test, the EpiSwitch PSE (Prostate Screening Test) combines the patient’s PSA result with validated biomarkers to predict the presence––or absence––of prostate cancer. Doctors and their patients are provided with the information needed to more accurately determine who can be referred for a prostate biopsy and who could be placed under active surveillance. ERG Protein Marker A marker used on prostate tissue after a biopsy, which measures ERG protein assays. This helps doctors identify patients who have the disease or have pre-cancerous lesions that indicate a patient is more likely to develop prostate cancer over time. Know Error A safeguard system of matching DNA samples from a biopsy to cheek swabs to confidently confirm a patient’s identity and diagnosis, ruling out contamination errors in the diagnostic process. PCA3 A urine test done in men with a high PSA level whose initial biopsy didn't show cancer. The test more accurately detects the possibility of prostate cancer by examining the expression of PCA3 – a gene specific to prostate cancer. The PCA3 score is used to determine the need for repeated biopsies. Phi The Prostate Health Index combines three blood tests that give a more accurate “Phi Score,” which gives information based on a high PSA to better determine the probability of finding cancer during a biopsy. SelectMDx A urine test for individuals with an elevated PSA level. It can provide better insight on personal prostate cancer risk for aggressive disease and whether you should have an initial prostate biopsy. StoreMyTumor Specializes in collecting, processing, and storing viable tumors for all types of cancers, which helps patients take advantage of the most personalized treatments and leading-edge diagnostics. Using StoreMyTumor, patients can store tissue collected from a surgery or biopsies. Storing tumor tissue increases treatment and diagnostic options. StoreMyTumor will coordinate the collection and storage process, and help doctors and patients connect to cutting-edge technologies that may be beyond the standard of care. Additional biomarker tests Biomarker testing may help you and your doctors decide on a treatment. Many prostate cancer biomarker tests are available. Some are used after a biopsy, some are used after a prostatectomy, and some are used if you have localized or advanced prostate cancer. Talk to your doctor about when your tumor should be tested and which biomarker test is right for you. Learn more about biomarkers and why biomarker testing is important. ArteraAI Prostate Test This AI-enabled test can determine whether a patient with localized prostate cancer has an aggressive form of the disease that may be likely to spread to other parts of the body. Additionally, for intermediate-risk patients, the test can predict whether a patient would benefit from adding androgen deprivation therapy to radiation therapy. Decipher® Decipher Prostate is a tissue-based biomarker test that provides actionable information for doctors and their patients to make treatment decisions across the spectrum of localized prostate cancer. FoundationOne®Liquid CDx This blood-based biomarker test looks for genetic mutations, helping to identify metastatic prostate cancer patients who may benefit from targeted therapies (PARP inhibitors). Genomic Prostate Score® The GPS test may help localized/early stage prostate cancer patients and their doctors determine what type of treatment is right based on their tumor’s characteristics. May also be referred to as the Oncotype DX GPS test. Prolaris® Prolaris is a test that may help predict how aggressive a patient’s prostate cancer is. Since it is performed on tissue already removed during a biopsy, men don’t need another procedure to have this test performed. ProstaVysion® ProstaVysion is a test that looks for two prostate cancer markers. The test may provide information about how aggressive the cancer is and which treatment options might be best. Read more about prostate cancer biomarkers and family history.
The most common screening tool for prostate cancer is the prostate-specific antigen (PSA) blood test. This test is usually the first step in any prostate cancer diagnosis. However, the PSA blood test by itself can't tell you if cancer is present.Recent research has yielded additional tests which look for genes, proteins, and other substances (called biomarkers or tumor markers) that can provide information about cancer. These tests, in addition to the PSA, DRE (Digital Rectal Exam), and biopsy, can give doctors and patients more information on how to determine the probability of both finding cancer during a biopsy and determining how aggressive that cancer is likely to be.
Additional screening and diagnostic tests While none of these tests are conclusive on their own, when performed in addition to a PSA test, DRE, and a biopsy, they can provide you with more information about your specific cancer and can help in making decisions about your care. 4KScore A blood test providing patient-specific probability of finding an aggressive form of prostate cancer during a biopsy. Doctors and patients can then make an informed decision on whether to have a biopsy. The test measures total PSA, free PSA, intact PSA, and for certain enzymes called kallikrein. An algorithm used with the patient’s age and physical exam gives a probability percentage of having aggressive disease. ConfirmMDX For patients with an initial negative biopsy, the ConfirmMDx test can make a significant prediction of patient outcome compared to other factors alone such as age, PSA and DRE results, race, and family history. It can help avoid repeat biopsies. EpiSwitch® PSE A simple blood test, the EpiSwitch PSE (Prostate Screening Test) combines the patient’s PSA result with validated biomarkers to predict the presence––or absence––of prostate cancer. Doctors and their patients are provided with the information needed to more accurately determine who can be referred for a prostate biopsy and who could be placed under active surveillance. ERG Protein Marker A marker used on prostate tissue after a biopsy, which measures ERG protein assays. This helps doctors identify patients who have the disease or have pre-cancerous lesions that indicate a patient is more likely to develop prostate cancer over time. Know Error A safeguard system of matching DNA samples from a biopsy to cheek swabs to confidently confirm a patient’s identity and diagnosis, ruling out contamination errors in the diagnostic process. PCA3 A urine test done in men with a high PSA level whose initial biopsy didn't show cancer. The test more accurately detects the possibility of prostate cancer by examining the expression of PCA3 – a gene specific to prostate cancer. The PCA3 score is used to determine the need for repeated biopsies. Phi The Prostate Health Index combines three blood tests that give a more accurate “Phi Score,” which gives information based on a high PSA to better determine the probability of finding cancer during a biopsy. SelectMDx A urine test for individuals with an elevated PSA level. It can provide better insight on personal prostate cancer risk for aggressive disease and whether you should have an initial prostate biopsy. StoreMyTumor Specializes in collecting, processing, and storing viable tumors for all types of cancers, which helps patients take advantage of the most personalized treatments and leading-edge diagnostics. Using StoreMyTumor, patients can store tissue collected from a surgery or biopsies. Storing tumor tissue increases treatment and diagnostic options. StoreMyTumor will coordinate the collection and storage process, and help doctors and patients connect to cutting-edge technologies that may be beyond the standard of care.
Additional biomarker tests Biomarker testing may help you and your doctors decide on a treatment. Many prostate cancer biomarker tests are available. Some are used after a biopsy, some are used after a prostatectomy, and some are used if you have localized or advanced prostate cancer. Talk to your doctor about when your tumor should be tested and which biomarker test is right for you. Learn more about biomarkers and why biomarker testing is important. ArteraAI Prostate Test This AI-enabled test can determine whether a patient with localized prostate cancer has an aggressive form of the disease that may be likely to spread to other parts of the body. Additionally, for intermediate-risk patients, the test can predict whether a patient would benefit from adding androgen deprivation therapy to radiation therapy. Decipher® Decipher Prostate is a tissue-based biomarker test that provides actionable information for doctors and their patients to make treatment decisions across the spectrum of localized prostate cancer. FoundationOne®Liquid CDx This blood-based biomarker test looks for genetic mutations, helping to identify metastatic prostate cancer patients who may benefit from targeted therapies (PARP inhibitors). Genomic Prostate Score® The GPS test may help localized/early stage prostate cancer patients and their doctors determine what type of treatment is right based on their tumor’s characteristics. May also be referred to as the Oncotype DX GPS test. Prolaris® Prolaris is a test that may help predict how aggressive a patient’s prostate cancer is. Since it is performed on tissue already removed during a biopsy, men don’t need another procedure to have this test performed. ProstaVysion® ProstaVysion is a test that looks for two prostate cancer markers. The test may provide information about how aggressive the cancer is and which treatment options might be best.
